CTLA4 and arthritic joint disease: Despite being generally well tolerated, CTLA4-Ig had a mixed record of success: efficacy was shown in arthritis, and the use in SLE and type 1 diabetes was also promising, but in some of the other immunological diseases, such as asthma, the use of abatacept was less beneficial[14–18].